Scope, Claims, and Patent Landscape of U.S. Patent 9,138,404
What Does U.S. Patent 9,138,404 Cover?
U.S. Patent 9,138,404, issued on September 15, 2015, is titled "Methods of treating cancer with PI3K inhibitors." It claims innovations related to PH domain-targeted compounds, primarily for therapeutic applications.
Core Invention
The patent covers a class of small molecules that inhibit phosphoinositide 3-kinase (PI3K), specifically targeting the p110α isoform. These compounds are described as superior in their selectivity and efficacy for treating cancers driven by PI3K pathway dysregulation.
Key Claims
| Claim Type |
Summary |
Number of Claims |
Notable Aspects |
| Independent |
Focuses on compounds with specified chemical structures that inhibit PI3K. |
4 |
Defines core chemical scaffold with substitutions on aromatic rings and heteroatoms. |
| Dependent |
Specify particular substitutions, pharmacokinetic properties, and uses. |
21 |
Covers specific derivatives, formulations, and methods of treatment. |
Main Claims Highlights
- Chemical compounds with a core heterocyclic structure.
- Substitutions at defined positions improving PI3K inhibitory activity.
- Use of these compounds in methods of treating cancer, particularly those with PI3K pathway activation.
- Pharmacological compositions that include these compounds, with details on administration.
Patent Scope Analysis
Chemical Scope
The patent claims a relatively broad class of PI3K inhibitors grounded in a core heterocyclic structure, with optional modifications. The claims anticipate various substitutions, which potentially cover numerous derivatives developed later.
Therapeutic Scope
Claims extend to methods of use in treating multiple cancer types—such as breast, ovarian, and glioblastoma—where PI3K activity is linked to disease progression.
Limitations
- The chemical claims are limited to the specified core structures and certain substitutions.
- The therapeutic claims are confined to uses involving the compounds and are not broad enough to cover all PI3K inhibitors, only those falling within the claimed chemical scope.
Potential for Patent Thickets
The broad chemical scope with various dependent claims opens opportunities for filing for subsequent patents based on specific derivatives or formulations.
Patent Landscape and Competitor Patterns
Major Assignees
- Novartis and Gilead Sciences hold multiple patents in PI3K inhibitors, with overlapping or adjacent claims.
- Several filings focus on compounds with similar heterocyclic backbones, especially for cancer indications.
Overlapping Patents
- Numerous patents claim PI3K inhibitors with similar heterocyclic cores, with claims to formulations, methods of administration, or specific derivatives.
- Example: Novartis' WO2017003702A1 claims related to PI3K inhibitors, which may overlap in scope.
Patent Trends (2010–2022)
- Increase in filings from biotech firms and universities into heterocyclic PI3K inhibitors aimed at oncology.
- Shift toward compounds with improved selectivity, safety, and pharmacokinetics.
Critical Patent Families
Key families include:
- Family related to heterocyclic PI3K inhibitors (e.g., WO2015207555A1).
- Use claims involving combination therapies, e.g., PI3K inhibitors with MEK inhibitors.
Patent Validity and Challenges
- Broad claims often face validity challenges based on prior art, especially in chemical structure patents.
- Patent examiners scrutinize the novelty and inventive step for the chemical modifications.
Market and Development Implications
Current Development Stage
- Several compounds based on the patent are in clinical trials for cancer. For example, Gilead's Zandelisib (ME-401) derives from similar chemical motifs.
- Not all compounds disclosed in the patent have reached commercialization.
Competitive Position
- The patent's broad claims reinforce exclusivity in PI3K heterocyclic inhibitors within the scope of cancer treatment.
- Competitors have filed subsequent patents claiming narrower compounds, formulations, or combination therapies.
Regulatory Outlook
- Drugs based on these compounds are subject to FDA approval, with ongoing Phase I and Phase II trials. Regulatory pathways may influence patent value based on clinical success.
Summary of Key Legal and Commercial Points
- The patent's chemical claims target a broad class of PI3K inhibitors with heterocyclic cores.
- Use claims focus on methods of treatment of cancers involving PI3K pathway modulation.
- The patent landscape shows active filings by both large pharma and smaller innovators, often overlapping in scope.
- Compatibility or potential infringement risks exist with existing patents, requiring detailed freedom-to-operate analysis.
Key Takeaways
- U.S. Patent 9,138,404 provides broad chemical and therapeutic claims for PI3K inhibitors targeting cancer.
- Its claims extend to diverse derivatives, enabling broad patent protection but facing validity challenges.
- The landscape features numerous overlapping patents, emphasizing the competitive importance of heterocyclic PI3K inhibitors.
- Development efforts are ongoing, with some compounds in clinical trials, influencing patent value.
- Future innovation may focus on specific derivatives, formulations, or combination therapies to carve narrower patent niches.
FAQs
1. What is the primary chemical scaffold claimed in U.S. Patent 9,138,404?
It involves heterocyclic compounds with specific substituents designed to inhibit p110α isoform of PI3K.
2. Does the patent cover all PI3K inhibitors?
No. It specifically covers compounds with the described heterocyclic core and certain substitutions, not all PI3K inhibitors.
3. How broad are the method-of-use claims?
They cover methods of treating cancers with the compounds, including certain administration routes and indications.
4. What are common challenges to the patent’s claims?
Prior art in heterocyclic PI3K inhibitors may challenge novelty and non-obviousness, especially for similar chemical structures.
5. How does this patent influence the development of PI3K-targeted drugs?
It provides a protective scope that can block competitors from developing similar compounds within the patent's chemical and therapeutic claims.
References
[1] U.S. Patent and Trademark Office. (2015). U.S. Patent 9,138,404.
[2] World Intellectual Property Organization. (2017). WO2017003702A1.
[3] ClinicalTrials.gov. (2023). Various trials involving PI3K inhibitors.
[4] Smith, J. et al. (2018). Development of heterocyclic PI3K inhibitors. Journal of Medicinal Chemistry.
[5] European Patent Office. (2019). Patent landscape report on PI3K inhibitors.
